Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Petmedix Ltd. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 examiners across 2 art units, indicating separate examination tracks.
GODDARD, LAURA B is the busiest examiner, with 1 pending matter. Counsel should preserve matter-specific responses while coordinating claim positions across the biotechnology portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GODDARD, LAURA B | 1 | 51.0% | +13.4% |
| LANDSMAN, ROBERT S | 1 | 81.4% | +13.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17996728 | HETERODIMERIC PROTEINS | LANDSMAN, ROBERT S | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18417116 | THERAPEUTIC ANTIBODIES | GODDARD, LAURA B | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18417116 | THERAPEUTIC ANTIBODIES | GODDARD, LAURA B | — |
| 17996728 | HETERODIMERIC PROTEINS | LANDSMAN, ROBERT S | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18417116 | THERAPEUTIC ANTIBODIES | GODDARD, LAURA B | 1642 | §103§112 | Non-Final OA | — | Pending | Jan 19, 2024 |
| 17996728 | HETERODIMERIC PROTEINS | LANDSMAN, ROBERT S | 1647 | §112 | Non-Final OA | — | Pending | Jul 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPetmedix Ltd. has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Laura B Goddard has the most, with 1 of Petmedix Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.